News | January 20, 2015

PotentiaMED Advisor Highlights Problems with Cancer Clinical Trials

Poor representative patient selection, exclusion of mitigating factors among issues to address

January 20, 2015 — The validity of randomized clinical trials in cancer has recently been called into question as many healthcare professionals are decrying the “experimerical” nature of these studies.

Jay F. Piccirillo, M.D., FACS, medical advisor for PotentiaMED, said, “The very nature of these studies is biased because they are often sponsored by pharmaceutical and device companies who have a vested interest in ensuring the studies have a positive outcome.”

 Piccirillo outlines the reasons randomized clinical trials are problematic:

  • Randomized clinical trials enroll younger and less racially diverse patients of the cancer population. “We know that roughly 53 percent of cancer patients are over the age of 65,” said Piccirillo, “Yet less than 33 percent of patients in the study are in this age group. Hence, we are getting data that is based on people who are much younger than the majority of our patients. Additionally, most of the people studied are white, meaning that we don’t have much data on people of color.”
  • Randomized clinical trials don’t consider comorbidity. “We have a saying in cancer treatment: ‘Sicker people die sooner,’” said Piccirillo. “This means that cancer patients with coexisting lung disease, heart disease, diabetes or other illnesses are less likely to improve with treatment and more likely to succumb quicker than cancer patients with less severe comorbidity. However, randomized clinical trials often exclude patients with comorbid ailments and so the results are not applicable to a large number of cancer patients.”
  • Randomized clinical trials don’t consider quality of life. “Randomized clinical trials seek ‘objective’ markers such as survival and tumor recurrence rates,” said Piccirillo, “These are important endpoints, however, patients increasingly also want information on quality of life and this important data simply isn’t available through clinical trials.”
  • Randomized clinical trials aren't publicized equally. “It is an inescapable truth that many of these trials are performed by companies who have a vested interest in the outcome,” said Piccirillo. “As such, they only tend to submit for publication and publicize positive findings. In fact, one study of selective publication bias found that 97 oercent (37 of 38) of positive trials were published while only 33 percent (8 of 24) of negative trials were published. This means that clinicians and patients who review the published medical literature receive a biased impression of treatment effectiveness.

 

“The reality is that only four percent of adults with cancer are involved in randomized clinical trials, yet healthcare professionals are using this information to determine the treatment for the other 96 percent of the population,” said Piccirillo. 

PotentiaMED was founded in 2009 with the goal of collecting and supplying invaluable treatment information for patients, doctors, hospitals, insurance providers, medical technology, and insurance providers. The PotentiaMED database offers patients all the data they need at their fingertips, from life expectancy to side effects to quality of life to future risk.

For more information: www.potentiamed.com

Related Content

Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
AI Detects Unsuspected Lung Cancer in Radiology Reports, Augments Clinical Follow-up
News | Artificial Intelligence | May 20, 2019
Digital Reasoning announced results from its automated radiology report analytics research. In a series of experiments...
New Study Evaluates Head CT Examinations and Patient Complexity
News | Neuro Imaging | May 17, 2019
Computed tomography (CT) of the head uses special X-ray equipment to help assess head injuries, dizziness and other...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Managing Architectural Distortion on Mammography Based on MR Enhancement
News | Mammography | May 15, 2019
High negative predictive values (NPV) in mammography architectural distortion (AD) without ultrasonographic (US)...
Icon Launches New Clinical Trial Patient Engagement Platform
Technology | Patient Engagement | May 14, 2019
Icon plc announced the release of its web-based clinical trial patient engagement platform, to provide patients with...
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
Screening MRI Detects BI-RADS 3 Breast Cancer in High-risk Patients
News | MRI Breast | May 09, 2019
When appropriate, short-interval follow-up magnetic resonance imaging (MRI) can be used to identify early-stage breast...
Ultrasonic Device Safe and Effective for Lung Vessel Sealing in Minimally Invasive Lobectomy
News | Interventional Radiology | May 06, 2019
According to a new study, an ultrasonic vessel-sealing device can improve patient outcomes by reducing the incidence of...
Pencil Beam Scanning Better Protects Children With Brain Tumors
News | Proton Therapy | May 01, 2019
A comparison of three types of radiotherapy for children's brain tumors suggests a type of proton therapy called pencil...